Bavarian Nordic (OTCMKTS:BVNRY) Posts Earnings Results

Bavarian Nordic (OTCMKTS:BVNRY) announced its quarterly earnings data on Friday. The company reported $0.46 earnings per share (EPS) for the quarter, Zacks reports. Bavarian Nordic had a return on equity of 9.32% and a net margin of 19.74%.

Bavarian Nordic Trading Up 10.0%

BVNRY stock traded up $0.99 during mid-day trading on Friday, reaching $10.95. The company’s stock had a trading volume of 23,999 shares, compared to its average volume of 3,210. Bavarian Nordic has a 12 month low of $8.67 and a 12 month high of $13.00. The business’s 50 day moving average price is $9.27 and its 200 day moving average price is $9.68. The company has a market cap of $2.60 billion, a price-to-earnings ratio of 14.41 and a beta of 1.20.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.